Jacobs Levy Equity Management
ABUS icon

Jacobs Levy Equity Management’s Arbutus Biopharma ABUS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-183,867
Closed -$351K – 935
2022
Q3 		$351K Buy
+183,867
New +$433K ﹤0.01% 874
2022
Q2 		– Sell
-55,713
Closed -$166K – 984
2022
Q1 		$166K Hold
55,713
– – ﹤0.01% 970
2021
Q4 		$217K Buy
+55,713
New +$216K ﹤0.01% 931
2019
Q3 		– Sell
-30,593
Closed -$64K – 910
2019
Q2 		$64K Buy
30,593
+8,797
+40% +$22.5K ﹤0.01% 926
2019
Q1 		$78K Buy
+21,796
New +$83.7K ﹤0.01% 939

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's ABUS Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 183,867 shares — an estimated $351K sold.

Jacobs Levy Equity Management first reported a position in ABUS in Q1 2019 and held it in 5 quarters. The position peaked at $351K in Q3 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 183,867 Arbutus Biopharma shares in Q4 2022, an estimated $351K.
  • Jacobs Levy Equity Management first reported a position in Arbutus Biopharma in Q1 2019 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Arbutus Biopharma position peaked at $351K in Q3 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.